Saakshi Medtech (SAAKSHI)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 31.15% and profit growth of 92.17% show strong momentum; latest quarter had ₹58 Cr sales and ₹7 Cr net profit.
• PEG ratio of 0.66 suggests the current P/E of 40.50 is less expensive relative to its growth rate.
• Piotroski F-Score of 7/9 indicates generally healthy financials across profitability, leverage, and efficiency metrics.
• Promoter holding of 73.89% aligns management's interests with minority shareholders.

Concerns

• P/E of 40.50 leaves little margin of safety if growth slows sharply.
• ROCE of only 6.09% raises questions about capital efficiency and competitive moat.
• Book value, ROE, and debt/equity are not available, so balance sheet strength cannot be properly assessed.
• No dividend yield and the stock trading well below its 52-week high of ₹331 suggest possible sentiment or execution risks.

AI Analysis

Let me start with what I like. Saakshi Medtech has grown sales at 31.15% and profits at 92.17%, and the latest quarter shows ₹58 Cr in sales with ₹7 Cr net profit—roughly a 12% margin. A PEG ratio of 0.66 suggests that at ₹205.50, the market is not paying enough for that growth, if it continues. The Piotroski F-Score of 7/9 tells me the company is not deteriorating; it is generating earnings and managing its finances reasonably. Promoter holding at 73.89% is a strong signal—owners have significant skin in the game. That matters to me. Yet I cannot ignore the price. At 40.5 times earnings, Mr Market is already expecting a great deal of future success. And ROCE of only 6.09% is hardly the kind of return on capital that defines a wonderful business. Benjamin Graham would say the margin of safety is thin. I also have no book value, no debt-to-equity figure, and no ROE to verify the strength of the balance sheet. Without those numbers, I am flying partially blind. The stock has fallen from ₹331 to ₹205.50, but a falling price is not by itself a bargain. I need to see whether the 92% profit growth is sustainable or merely a one-time boost. I would not rush to buy at this price, but I would put it on my watchlist. If the next few quarters continue to show this kind of profit growth and return on capital improves, the high P/E will look more reasonable. For now, it is a fast grower, but a fast grower still has to prove its moat and capital efficiency before I commit my money.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer